Frederick Pei Li

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Frederick Pei Li (born 1940) is a Chinese-American physician.[1] He was born in Canton, China (Guangzhou), and raised in New York City where his parents operated a Chinese restaurant. He is a pioneer researcher of cancer among genetically predisposed families described as Li-Fraumeni syndrome. He received a B.A. in physics from New York University, an M.D. from the University of Rochester, and M.A. in demography from Georgetown University. In 1967 he joined the Epidemiology Branch of the National Cancer Institute (NCI). He served for 24 years, mostly at the NCI's field station at the Dana-Farber Cancer Institute in Boston. In 1991, he became head of Dana-Farber's Division of Cancer Epidemiology and Control, and retired in 2008.

Currently, Dr. Li is Professor of Clinical Cancer Epidemiology at the Harvard School of Public Health, Professor of Medicine at the Harvard Medical School, and the Harry and Elsa Jiler American Cancer Society Clinical Research Professor. In 1996, Dr. Li was appointed by President Bill Clinton to NCI's National Cancer Advisory Board.

Research Interests[edit]

Molecular Epidemiology of Hereditary Cancers Recent data have established that the basic molecular defects in cancer are genetic changes that result in loss of normal cellular control mechanisms. Some of these mutations can be inherited through the germline. "I have been studying inherited susceptibility of cancer through affected families. The goal is to identify genes that are involved in cancer development".

"I was attracted to studies of cancer families because epidemiological studies show that virtually all cancers manifest a tendency to aggregate in families. Close relatives of a cancer patient are at increased risk of that neoplasm, and perhaps other forms of cancer. The excess site-specific cancer risk is exceptionally high for carriers of certain cancer genes, in whom the attack rate can approach 100 percent. In candidate cancer families, the possibility that clustering is on the basis of chance must be excluded through epidemiological studies that establish the presence of an excess cancer risk. Predisposed families are candidates for laboratory studies to identify the inherited susceptibility factors. These investigations have led to the identification and isolation of human cancer genes, the tumor suppressor genes. These cancer genes are among more than 200 single-gene traits associated with the development of cancer. Approximately a dozen inherited susceptibility genes have been definitively identified, and many more are being sought. From studies of retinoblastoma and other rare cancers, important new information was generated about the fundamental biology of cancers that arise in many patients. Isolation of an inherited cancer susceptibility gene provides opportunities for presymptomatic testing of at-risk relatives. However, testing of healthy individuals also raise important issues regarding informed consent, confidentiality and potential for adverse psychological, social and economic effects."

"My colleagues and I are using families with inherited mutations in the p53 gene, which predisposes to breast cancer and diverse childhood cancers, as a model for developing a genetic testing program".

Awards[edit]

  • 1999 Medal of Honor for Clinical Research, American Cancer Society
  • 1998 Harry and Elsa Jiler Clinical Research Professorship, American Cancer Society
  • 1995 Award for Research Excellence in Cancer Epidemiology and Prevention, American Association for Cancer Research/American Cancer Society
  • 1995 Charles S. Mott Prize, General Motors Cancer Research Foundation

See also[edit]

References[edit]

External links[edit]